KR20070085093A - Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한신규한 신경 보호 방법 - Google Patents

Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한신규한 신경 보호 방법 Download PDF

Info

Publication number
KR20070085093A
KR20070085093A KR1020067022076A KR20067022076A KR20070085093A KR 20070085093 A KR20070085093 A KR 20070085093A KR 1020067022076 A KR1020067022076 A KR 1020067022076A KR 20067022076 A KR20067022076 A KR 20067022076A KR 20070085093 A KR20070085093 A KR 20070085093A
Authority
KR
South Korea
Prior art keywords
ampk
stroke
ischemic
pampk
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067022076A
Other languages
English (en)
Korean (ko)
Inventor
루이스 디. 매클러
홍 리
질 맥패든
가브리엘 브이. 로네트
Original Assignee
파스젠, 엘엘씨.
더 존스 홉킨스 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파스젠, 엘엘씨., 더 존스 홉킨스 유니버시티 filed Critical 파스젠, 엘엘씨.
Publication of KR20070085093A publication Critical patent/KR20070085093A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020067022076A 2004-03-24 2005-03-23 Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한신규한 신경 보호 방법 Ceased KR20070085093A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55600004P 2004-03-24 2004-03-24
US60/556,000 2004-03-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020127016911A Division KR101283416B1 (ko) 2004-03-24 2005-03-23 Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한 신규한 신경보호 방법

Publications (1)

Publication Number Publication Date
KR20070085093A true KR20070085093A (ko) 2007-08-27

Family

ID=35056772

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020067022076A Ceased KR20070085093A (ko) 2004-03-24 2005-03-23 Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한신규한 신경 보호 방법
KR1020127016911A Expired - Fee Related KR101283416B1 (ko) 2004-03-24 2005-03-23 Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한 신규한 신경보호 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020127016911A Expired - Fee Related KR101283416B1 (ko) 2004-03-24 2005-03-23 Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한 신규한 신경보호 방법

Country Status (11)

Country Link
US (1) US8293791B2 (https=)
EP (1) EP1734973A4 (https=)
JP (1) JP2008504228A (https=)
KR (2) KR20070085093A (https=)
CN (1) CN101132802A (https=)
AU (1) AU2005226731A1 (https=)
BR (1) BRPI0509085A (https=)
CA (1) CA2560843A1 (https=)
IL (1) IL178242A0 (https=)
MX (1) MXPA06010916A (https=)
WO (1) WO2005092068A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06010916A (es) 2004-03-24 2007-07-25 Fasgen Llc Novedoso metodo de proteccion neurologica mediante inhibicion farmacologica de proteina quinasa activada por amp.
KR101152607B1 (ko) 2005-12-20 2012-06-05 에스케이케미칼주식회사 ６-[４-(２-피페리딘-1-일-에톡시)-페닐]-３-피리딘-４-일-피라졸로[１,５-ａ]피리미딘의 제조방법
KR101787116B1 (ko) 2009-01-28 2017-10-18 케러 테라퓨틱스, 인코포레이티드 바이시클릭 피라졸로-헤테로사이클
US7741350B1 (en) * 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
EP2978307B1 (en) 2013-03-28 2018-12-26 The Trustees of Columbia University in the City of New York Reperfusion with omega-3 glycerides promotes donor organ protection for transplantation
KR101532211B1 (ko) * 2014-04-30 2015-06-30 세종대학교산학협력단 Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물 및 방법
CN119868551B (zh) * 2024-11-28 2026-04-14 四川大学华西医院 F-box蛋白48的抑制剂的新用途和治疗缺血性脑血管病的药物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9602080D0 (en) * 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
CO5180581A1 (es) 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
IL147696A0 (en) * 2001-01-25 2002-08-14 Pfizer Prod Inc Combination therapy
US6423705B1 (en) * 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
MXPA06010916A (es) 2004-03-24 2007-07-25 Fasgen Llc Novedoso metodo de proteccion neurologica mediante inhibicion farmacologica de proteina quinasa activada por amp.

Also Published As

Publication number Publication date
US20090137665A1 (en) 2009-05-28
MXPA06010916A (es) 2007-07-25
EP1734973A4 (en) 2010-08-04
JP2008504228A (ja) 2008-02-14
EP1734973A2 (en) 2006-12-27
AU2005226731A1 (en) 2005-10-06
WO2005092068A2 (en) 2005-10-06
KR101283416B1 (ko) 2013-07-08
BRPI0509085A (pt) 2007-08-21
IL178242A0 (en) 2007-03-08
US8293791B2 (en) 2012-10-23
CN101132802A (zh) 2008-02-27
KR20120078756A (ko) 2012-07-10
CA2560843A1 (en) 2005-10-06
WO2005092068A3 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
McCullough et al. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke
Correa et al. Curcumin maintains cardiac and mitochondrial function in chronic kidney disease
US6288089B1 (en) Use of kinase inhibitors for treating neurodegenerative diseases
Paulus The role of nitric oxide in the failing heart
EP2601964B1 (en) Balanol compounds for use in treating pain
Leeds et al. Neurotrophins protect against cytosine arabinoside-induced apoptosis of immature rat cerebellar neurons
CA2427430A1 (en) Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
KR101283416B1 (ko) Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한 신규한 신경보호 방법
EP1093379B1 (en) Use of inhibitors of protein kinase c epsilon to treat pain
Mukhopadhyay et al. Role of MAPK/AP-1 signaling pathway in the protection of CEES-induced lung injury by antioxidant liposome
US20030215428A1 (en) Methods for stimulating nervous system regeneration and repair by regulating arginase I and polyamine synthesis
Guo et al. Free radicals are involved in continuous activation of nonreceptor tyrosine protein kinase c-Src after ischemia/reperfusion in rat hippocampus
Abe et al. The phosphatidylinositol-3 kinase/Akt pathway mediates geranylgeranylacetone-induced neuroprotection against cerebral infarction in rats
Nowak et al. Deletion of protein kinase C-ε attenuates mitochondrial dysfunction and ameliorates ischemic renal injury
Ciocci Pardo et al. Myocardial and mitochondrial effects of the anhydrase carbonic inhibitor ethoxzolamide in ischemia‐reperfusion
Wang et al. Augmentation of functional recovery via ROCK/PI3K/AKT pathway by Fasudil Hydrochloride in a rat sciatic nerve transection model
PL209912B1 (pl) Zastosowanie inhibitora kinazy tyrozynowej w medycynie
WO2012117334A1 (en) Mglur5 positive allosteric modulators for use in the treatment phelan-mcdermid syndrome
Ceolotto et al. Effect of protein kinase C and insulin on Na+/H+ exchange in red blood cells of essential hypertensives
HK1118217A (en) Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase
JP2002511876A (ja) 心臓におけるインシュリン耐性を治療し、プロテインキナーゼｂ（ｐｋｂ）活性を強化するための組成物における成長ホルモンの使用
US20160095837A1 (en) Modulation of mitochondrial calcium uniporter activity for treating and preventing arrhythmias
Chin Mechanism (s) of ischaemia/reperfusion injury and cardioprotection
Bsc et al. Neuronal injury in NCX3 knockout mice following permanent focal cerebral ischemia and in NCX3 knockout cortical neuronal cultures following oxygen-glucose deprivation and glutamate exposure
Grant et al. The role of signal transduction pathways in drug and radiation resistance

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20061024

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100316

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110920

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120228

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110920

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20120530

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20120228

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20120720

Appeal identifier: 2012101005210

Request date: 20120530

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20120629

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20120702

WITB Written withdrawal of application
J301 Trial decision

Free format text: TRIAL NUMBER: 2012101005210; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20120530

Effective date: 20120720

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20120530

Effective date: 20120720

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20120720

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20120530

Decision date: 20120720

Appeal identifier: 2012101005210